Bleeding out: Theranos oozes with corporate governance lessons


A year ago, Theranos was a Silicon Valley health tech “unicorn” praised for breakthrough advancements in blood testing. Now it’s under civil and criminal investigation for defrauding investors. The role Theranos’ board has played in this is already shaping up to be a pointed object lesson for board best practices ...

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.